WP
SLNO

Woodline Partners’s Soleno Therapeutics SLNO Stock Holding History

Woodline Partners’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,112,104
Closed -$37.2M – 1134
2026
Q1 		$37.2M Buy
1,112,104
+326
+0% +$12.8K 0.14% 191
2025
Q4 		$51.5M Buy
1,111,778
+840,946
+311% +$46.1M 0.2% 120
2025
Q3 		$18.3M Sell
270,832
-78,832
-23% -$5.84M 0.09% 302
2025
Q2 		$29.3M Hold
349,664
– – 0.15% 201
2025
Q1 		$25M Buy
349,664
+48,102
+16% +$2.34M 0.16% 185
2024
Q4 		$13.6M Sell
301,562
-100,521
-25% -$5.21M 0.09% 286
2024
Q3 		$20.3M Buy
402,083
+82,878
+26% +$3.97M 0.17% 191
2024
Q2 		$13M Buy
319,205
+212,745
+200% +$9.02M 0.12% 220
2024
Q1 		$4.56M Sell
106,460
-93,540
-47% -$4.23M 0.04% 369
2023
Q4 		$8.05M Sell
200,000
-63,860
-24% -$1.82M 0.09% 254
2023
Q3 		$7.79M Buy
+263,860
New +$1.6M 0.09% 249

Woodline Partners's SLNO Position: Q2 2026 in Review

Woodline Partners sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 1,112,104 shares — an estimated $37.2M sold.

Woodline Partners first reported a position in SLNO in Q3 2023 and held it in 11 quarters. The position peaked at $51.5M in Q4 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

  • Woodline Partners reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Woodline Partners sold 1,112,104 Soleno Therapeutics shares in Q2 2026, an estimated $37.2M.
  • Woodline Partners first reported a position in Soleno Therapeutics in Q3 2023 and held it in 11 quarters.
  • Woodline Partners's Soleno Therapeutics position peaked at $51.5M in Q4 2025.
  • 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.